Clinical Trials (Phase I)

Found 13,272 articles

• Merck Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) via Subdermal Implant

  7/23/2019

  Phase 1 Data Presented Today at IAS 2019

• Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer's Disease

  7/23/2019

  IND Cleared and First Phase 1 Study Subject Dosed

• 

  Clinical Catch-up for July 15-19

  7/22/2019

  Here's a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.

• Achillion’s ACH-5228 Achieves Positive Results In Phase 1 Multiple Ascending Dose Study In Healthy Volunteers

  7/22/2019

  Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced results from their Phase 1 multiple ascending dose study with ACH-5228 outside of the United States.

• BioXcel Therapeutics Announces BXCL501 Met Primary Endpoint in Phase 1b Placebo-Controlled Trial in the Treatment of Agitation in Patients with Schizophrenia

  7/22/2019

  BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced positive top-line results from the adaptive Phase 1b, randomized, double-blind, placebo-controlled, multi-center, U.S. trial, evaluating multiple doses of BXCL501 for acute treatment of agitation in 135 patients with schizophrenia.

• Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center

  7/22/2019

  Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) in New York, NY will investigate the potential use of Kazia's investigational new drug, GDC-0084, in combination with radiotherapy in a phase I clinical trial for cancer

• Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV

  7/22/2019

  Gilead Sciences, Inc. (NASDAQ: GILD) today presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function.

• Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US

  7/22/2019

  Ascentage Pharma, announced that the company was notified by the U.S. Food & Drug Administration on the clearance of the Investigational New Drug application which allows the company to initiate its Phase Ib clinical trial of HQP1351, a novel drug candidate developed by Ascentage Pharma, for the treatment of patients with tyrosine kinase inhibitors-resistant chronic myeloid leukemia in the United States.

• Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled

  7/22/2019

  Biohaven Pharmaceutical Holding Company Ltd. announced that enrollment in the T2 Protect AD Study, a Phase 2/3 clinical trial of troriluzole in Alzheimer's disease, is progressing on timelines with more than 400 subjects enrolled and over 180 subjects randomized to study treatment.

• CStone receives approval in China to initiate ivosidenib Phase I bridging registrational study for the treatment of IDH1 mutant relapsed or refractory AML

  7/22/2019

  CStone Pharmaceuticals announced that it has received approval from China National Medical Products Administration to initiate a Phase I bridging registrational study of ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation.

• Personalized gene-edited immune cell therapy for patients with solid cancers: New data establishes approach for verifying patient-specific cancer mutation targets

  7/21/2019

  PACT's gene-edited T cells were observed to kill tumor cells by targeting patient-specific tumor mutation targets in non-clinical testing

• 

  Gilead Snaps up Antiviral Programs From Novartis, Follows Slew of Other Pipeline-Bolstering Deals

  7/19/2019

  In addition to the three preclinical assets from Novartis, Gilead has recently entered into deals to develop therapies for HIV, RA and NASH.
• 

  Roche and Novo Nordisk Top Clinical Trial Transparency Survey

  7/19/2019

  In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.

• Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501

  7/19/2019

  Aridis Pharmaceuticals, Inc. announced that the European Medicines Agency has granted Orphan Drug Designation to AR-501, the Company's inhaled formulation of gallium citrate for treatment of lung infection in patients with cystic fibrosis.

• 

  BioSpace Global Roundup, July 18

  7/18/2019

  Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.

• Sernova's Phase I/II US Clinical Trial for Type-1 Diabetes Advances Following Positive Preliminary Safety and Efficacy Data

  7/18/2019

  Sernova Corp. (TSXV:SVA) (FSE:PSH) (OTCQB:SEOVF), a clinical-stage regenerative medicine company today announced that its human Phase I/II clinical trial for type-1 diabetes is advancing with additional patients for device and cell transplantation.

• NuCana Announces First Patients Dosed in Phase I Study of NUC-7738

  7/18/2019

   NuCana  plc  (NASDAQ:  NCNA)  a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, today announced that the first patients have been dosed in the Phase I study of NUC-7738.

• Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases

  7/18/2019

  Collaboration advances Silence's proprietary platform in the growing field of RNAi technology

• Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics

  7/18/2019

  Bridge Biotherapeutics stands to receive up to more than EUR 1.1 billion assuming all milestones are met

• LifeMax Receives Rare Pediatric Disease Designation for LM-030 for the Treatment of Netherton Syndrome

  7/18/2019

  LifeMax Laboratories, Inc. announced that the Food & Drug Administration granted rare pediatric disease designation to LM-030, an investigational therapy licensed from Novartis and ready to enter into pivotal clinical trials for the treatment of Netherton Syndrome.